The global kidney transplant immunosuppressant drugs market is a rapidly evolving sector driven by the increasing incidence of kidney diseases, advancements in immunosuppressive therapies, and a growing number of kidney transplants worldwide. The rate of kidney transplants worldwide has increased over the past few years reaching 17.1 transplants per million population in 2022. Rising prevalence of kidney diseases and advancements in immunosuppressive therapy are key drivers of the kidney transplant immunosuppressant drugs market. These factors contribute significantly to the increasing demand for effective therapies that prevent organ rejection and improve transplant success rates.
